Mohamed Kahila, MBBCh
Assistant ProfessorDownloadHi-Res Photo
Cards
Appointments
Pathology
Primary
Contact Info
About
Titles
Assistant Professor
Biography
Dr. Kahila is an Assistant Professor of Pathology. He practices breast and molecular genetics pathology at Yale New Haven Hospital.
Dr. Kahila obtained his MBBCh degree from Ain Shams University, Egypt. He did a research fellowship with Dr. Robert Mutter at The Mayo Clinic Rochester, where he worked on new strategies to sensitize chemo and radiotherapy resistance triple-negative breast cancer using DNA repair inhibitors. He did his anatomic/clinical pathology residency at SUNY Downstate Medical Center, New York State University, followed by a breast pathology fellowship at the Brigham and Women`s Hospital in Boston and a Molecular Genetic Pathology fellowship at the Yale New Haven Hospital. Dr. Kahila is a multidisciplinary team member who cares for cancer patients at Smilow Cancer Hospital and Yale Cancer Center.
Appointments
Education & Training
- Clinical Fellow
- Brigham and Women`s Hospital (2022)
- Resident
- Downstate Health Sciences University (2021)
- Postdoctoral Fellow
- The Mayo Clinic Rochester
- MBBCh
- Ain Shams University
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Mohamed Kahila's published research.
Publications Timeline
A big-picture view of Mohamed Kahila's research output by year.
Kim Blenman, PhD, MS
Lajos Pusztai, MD, DPhil
11Publications
21Citations
Publications
2023
Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
Thagaard J, Broeckx G, Page D, Jahangir C, Verbandt S, Kos Z, Gupta R, Khiroya R, Abduljabbar K, Haab G, Acs B, Akturk G, Almeida J, Alvarado‐Cabrero I, Amgad M, Azmoudeh‐Ardalan F, Badve S, Baharun N, Balslev E, Bellolio E, Bheemaraju V, Blenman K, Fujimoto L, Bouchmaa N, Burgues O, Chardas A, Cheang M, Ciompi F, Cooper L, Coosemans A, Corredor G, Dahl A, Portela F, Deman F, Demaria S, Hansen J, Dudgeon S, Ebstrup T, Elghazawy M, Fernandez‐Martín C, Fox S, Gallagher W, Giltnane J, Gnjatic S, Gonzalez‐Ericsson P, Grigoriadis A, Halama N, Hanna M, Harbhajanka A, Hart S, Hartman J, Hauberg S, Hewitt S, Hida A, Horlings H, Husain Z, Hytopoulos E, Irshad S, Janssen E, Kahila M, Kataoka T, Kawaguchi K, Kharidehal D, Khramtsov A, Kiraz U, Kirtani P, Kodach L, Korski K, Kovács A, Laenkholm A, Lang‐Schwarz C, Larsimont D, Lennerz J, Lerousseau M, Li X, Ly A, Madabhushi A, Maley S, Narasimhamurthy V, Marks D, McDonald E, Mehrotra R, Michiels S, Minhas F, Mittal S, Moore D, Mushtaq S, Nighat H, Papathomas T, Penault‐Llorca F, Perera R, Pinard C, Pinto‐Cardenas J, Pruneri G, Pusztai L, Rahman A, Rajpoot N, Rapoport B, Rau T, Reis‐Filho J, Ribeiro J, Rimm D, Roslind A, Vincent‐Salomon A, Salto‐Tellez M, Saltz J, Sayed S, Scott E, Siziopikou K, Sotiriou C, Stenzinger A, Sughayer M, Sur D, Fineberg S, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson E, Tramm T, Tran W, van der Laak J, van Diest P, Verghese G, Viale G, Vieth M, Wahab N, Walter T, Waumans Y, Wen H, Yang W, Yuan Y, Zin R, Adams S, Bartlett J, Loibl S, Denkert C, Savas P, Loi S, Salgado R, Stovgaard E. Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer. The Journal Of Pathology 2023, 260: 498-513. PMID: 37608772, PMCID: PMC10518802, DOI: 10.1002/path.6155.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTumor-infiltrating lymphocytesTriple-negative breast cancerBreast cancerTIL assessmentHER2-positive breast cancerRoutine clinical managementTIL evaluationTumor-immune interactionsClinical managementDiscordant assessmentsClinical significancePrognostic biomarkerTIL quantificationCancerDaily practicePatientsTrialsTissue patternsAssessmentLymphocytesBiomarkersSpatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
Page D, Broeckx G, Jahangir C, Verbandt S, Gupta R, Thagaard J, Khiroya R, Kos Z, Abduljabbar K, Haab G, Acs B, Akturk G, Almeida J, Alvarado‐Cabrero I, Azmoudeh‐Ardalan F, Badve S, Baharun N, Bellolio E, Bheemaraju V, Blenman K, Fujimoto L, Bouchmaa N, Burgues O, Cheang M, Ciompi F, Cooper L, Coosemans A, Corredor G, Portela F, Deman F, Demaria S, Dudgeon S, Elghazawy M, Ely S, Fernandez‐Martín C, Fineberg S, Fox S, Gallagher W, Giltnane J, Gnjatic S, Gonzalez‐Ericsson P, Grigoriadis A, Halama N, Hanna M, Harbhajanka A, Hardas A, Hart S, Hartman J, Hewitt S, Hida A, Horlings H, Husain Z, Hytopoulos E, Irshad S, Janssen E, Kahila M, Kataoka T, Kawaguchi K, Kharidehal D, Khramtsov A, Kiraz U, Kirtani P, Kodach L, Korski K, Kovács A, Laenkholm A, Lang‐Schwarz C, Larsimont D, Lennerz J, Lerousseau M, Li X, Ly A, Madabhushi A, Maley S, Narasimhamurthy V, Marks D, McDonald E, Mehrotra R, Michiels S, Minhas F, Mittal S, Moore D, Mushtaq S, Nighat H, Papathomas T, Penault‐Llorca F, Perera R, Pinard C, Pinto‐Cardenas J, Pruneri G, Pusztai L, Rahman A, Rajpoot N, Rapoport B, Rau T, Reis‐Filho J, Ribeiro J, Rimm D, Vincent‐Salomon A, Salto‐Tellez M, Saltz J, Sayed S, Siziopikou K, Sotiriou C, Stenzinger A, Sughayer M, Sur D, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson E, Tramm T, Tran W, van der Laak J, van Diest P, Verghese G, Viale G, Vieth M, Wahab N, Walter T, Waumans Y, Wen H, Yang W, Yuan Y, Adams S, Bartlett J, Loibl S, Denkert C, Savas P, Loi S, Salgado R, Stovgaard E. Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer. The Journal Of Pathology 2023, 260: 514-532. PMID: 37608771, PMCID: PMC11288334, DOI: 10.1002/path.6165.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
2022
Heterotopic Ossification After Revision Carpal Tunnel Release Causing Mixed Ulnar and Median Compression Neuropathy.
Maheshwari AV, Dua K, Wham B, Kahila M, Kolla S, Stracher MA. Heterotopic Ossification After Revision Carpal Tunnel Release Causing Mixed Ulnar and Median Compression Neuropathy. The Journal Of Hand Surgery 2022, 47: 94.e1-94.e6. PMID: 33579592, DOI: 10.1016/j.jhsa.2020.12.009.Peer-Reviewed Original Research
2020
Incorporation of Biologic Response Variance Modeling Into the Clinic: Limiting Risk of Brachial Plexopathy and Other Late Effects of Breast Cancer Proton Beam Therapy.
Mutter RW, Jethwa KR, Wan Chan Tseung HS, Wick SM, Kahila MMH, Viehman JK, Shumway DA, Corbin KS, Park SS, Remmes NB, Whitaker TJ, Beltran CJ. Incorporation of Biologic Response Variance Modeling Into the Clinic: Limiting Risk of Brachial Plexopathy and Other Late Effects of Breast Cancer Proton Beam Therapy. Practical Radiation Oncology 2020, 10: e71-e81. PMID: 31494289, PMCID: PMC7734652, DOI: 10.1016/j.prro.2019.08.011.Peer-Reviewed Original Research
2019
Congenital Macronodular Eyelid Juvenile Xanthogranuloma.
Chubak A, Kahila M, Shinder R. Congenital Macronodular Eyelid Juvenile Xanthogranuloma. Ophthalmology 2019, 126: 1229. PMID: 31443784, DOI: 10.1016/j.ophtha.2019.05.011.Peer-Reviewed Original ResearchPD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.
Tu X, Qin B, Zhang Y, Zhang C, Kahila M, Nowsheen S, Yin P, Yuan J, Pei H, Li H, Yu J, Song Z, Zhou Q, Zhao F, Liu J, Zhang C, Dong H, Mutter RW, Lou Z. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy. Molecular Cell 2019, 74: 1215-1226.e4. PMID: 31053471, PMCID: PMC6737939, DOI: 10.1016/j.molcel.2019.04.005.Peer-Reviewed Original Research
2018
ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.
Tu X, Kahila MM, Zhou Q, Yu J, Kalari KR, Wang L, Harmsen WS, Yuan J, Boughey JC, Goetz MP, Sarkaria JN, Lou Z, Mutter RW. ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer. Molecular Cancer Therapeutics 2018, 17: 2462-2472. PMID: 30166399, PMCID: PMC6215494, DOI: 10.1158/1535-7163.MCT-18-0470.Peer-Reviewed Original ResearchPatient-reported outcomes of catheter-based accelerated partial breast brachytherapy and whole breast irradiation, a single institution experience.
Jethwa KR, Kahila MM, Mara KC, Harmsen WS, Routman DM, Pumper GM, Corbin KS, Sloan JA, Ruddy KJ, Hieken TJ, Park SS, Mutter RW. Patient-reported outcomes of catheter-based accelerated partial breast brachytherapy and whole breast irradiation, a single institution experience. Breast Cancer Research And Treatment 2018, 169: 189-196. PMID: 29349713, DOI: 10.1007/s10549-018-4665-6.Peer-Reviewed Original Research
2017
Initial clinical experience of postmastectomy intensity modulated proton therapy in patients with breast expanders with metallic ports.
Mutter RW, Remmes NB, Kahila MM, Hoeft KA, Pafundi DH, Zhang Y, Corbin KS, Park SS, Yan ES, Lemaine V, Boughey JC, Beltran CJ. Initial clinical experience of postmastectomy intensity modulated proton therapy in patients with breast expanders with metallic ports. Practical Radiation Oncology 2017, 7: e243-e252. PMID: 28341315, DOI: 10.1016/j.prro.2016.12.002.Peer-Reviewed Original ResearchImmediate tissue expander or implant-based breast reconstruction does not compromise the oncologic delivery of post-mastectomy radiotherapy (PMRT).
Jethwa KR, Kahila MM, Whitaker TJ, Harmsen WS, Corbin KS, Park SS, Yan ES, Lemaine V, Boughey JC, Mutter RW. Immediate tissue expander or implant-based breast reconstruction does not compromise the oncologic delivery of post-mastectomy radiotherapy (PMRT). Breast Cancer Research And Treatment 2017, 164: 237-244. PMID: 28417333, DOI: 10.1007/s10549-017-4241-5.Peer-Reviewed Original Research